Variable access to antiviral treatment of chronic hepatitis B in Canada: A descriptive study
Background: Antiviral treatment for chronic hepatitis B is costly, which presents challenges for universal drug coverage for the estimated 480 000 people with the disease in Canada. We appraised criteria for reimbursement of chronic hepatitis B antivirals by public drug plans in Canada.
Year of Publication: 2019
Authors: Stephen Congly, Mayur Brahmania
Journal Title: CMAJ Open